STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
复制标题
DOI：
10.3390/cancers14164034
复制
发表时间：
2022-08-20
期刊：
影响因子：
5.2
通讯作者：
Kelly, William K.
中科院分区：
文献类型：
--
作者：
Xu, Michael;Evans, Latese;Bizzaro, Candice L.;Quaglia, Fabio;Verrillo, Cecilia E.;Li, Li;Stieglmaier, Julia;Schiewer, Matthew J.;Languino, Lucia R.;Kelly, William K.
关键词：
尽管最近在前列腺癌的治疗方面取得了进展，但转移性去势抵抗性前列腺癌仍然导致显着的发病率和死亡率。对转移性去势抵抗性前列腺癌中高表达蛋白的新研究表明，前列腺六跨膜上皮抗原 1-4 (STEAP1-4) 是前列腺癌侵袭性和转移的重要驱动因素。特别是，STEAP1 在前列腺癌细胞的质膜上高表达，作为潜在的治疗靶点而受到广泛关注。本综述重点介绍了有关 STEAP1-4 的已知信息，并确定了需要进一步研究的知识差距。前列腺六跨膜上皮抗原 1-4 (STEAP1-4) 组成参与铁和铜稳态及其他细胞过程的金属蛋白酶家族。迄今为止，已知有 5 个同源物：STEAP1、STEAP1B、STEAP2、STEAP3 和 STEAP4。在前列腺癌中，STEAP1、STEAP2 和 STEAP4 过表达，而 STEAP3 表达下调。尽管 STEAP1-4 的金属还原酶活性已有详细记录，但其其他生物学功能却没有详细记录。此外，STEAP异源三聚体、同源三聚体、异源二聚体和同源二聚体的特性和表达水平尚不清楚。尽管如此，过去几十年的研究为研究 STEAP1-4 作为前列腺癌的潜在生物标志物和治疗靶点提供了足够的动力。特别是，STEAP1 是许多新兴免疫疗法的靶点。在此，我们概述了 STEAP1-4 的结构、生理学和病理生理学，为过去和当前将 STEAP1-4 转化为临床的努力提供背景。
Despite recent therapeutic advances in the treatment of prostate cancer, metastatic castration-resistant prostate cancer continues to cause significant morbidity and mortality. New research into highly expressed proteins in metastatic castration-resistant prostate cancer shows that Six-Transmembrane Epithelial Antigen of the Prostate 1–4 (STEAP1–4) are significant drivers of prostate cancer aggressiveness and metastasis. STEAP1, in particular, is highly expressed on the plasma membrane of prostate cancer cells and has received significant attention as a potential therapeutic target. This review highlights what is known about STEAP1–4 and identifies knowledge gaps that require further research. Six-Transmembrane Epithelial Antigen of the Prostate 1–4 (STEAP1–4) compose a family of metalloproteinases involved in iron and copper homeostasis and other cellular processes. Thus far, five homologs are known: STEAP1, STEAP1B, STEAP2, STEAP3, and STEAP4. In prostate cancer, STEAP1, STEAP2, and STEAP4 are overexpressed, while STEAP3 expression is downregulated. Although the metalloreductase activities of STEAP1–4 are well documented, their other biological functions are not. Furthermore, the properties and expression levels of STEAP heterotrimers, homotrimers, heterodimers, and homodimers are not well understood. Nevertheless, studies over the last few decades have provided sufficient impetus to investigate STEAP1–4 as potential biomarkers and therapeutic targets for prostate cancer. In particular, STEAP1 is the target of many emerging immunotherapies. Herein, we give an overview of the structure, physiology, and pathophysiology of STEAP1–4 to provide context for past and current efforts to translate STEAP1–4 into the clinic.
登录
查看更多内容
影响因子：
4.7
作者：
Guo Q;Li L;Hou S;Yuan Z;Li C;Zhang W;Zheng L;Li X
通讯作者：
Li X
影响因子：
3.4
作者：
Gomes, Ines Margarida;Rocha, Sandra Moreira;Maia, Claudio Jorge
通讯作者：
Maia, Claudio Jorge
影响因子：
5.6
作者：
Chen, Huaijun;Xu, Chaoran;Chen, Gao
通讯作者：
Chen, Gao
影响因子：
5.8
作者：
Alves, Pedro M. S.;Faure, Olivier;Kosmatopoulos, Kostas
通讯作者：
Kosmatopoulos, Kostas
影响因子：
11.2
作者：
Garcia-Hernandez, Maria de la Luz;Gray, Andrew;Kast, W. Martin
通讯作者：
Kast, W. Martin